The FDA has authorized lenacapavir (LEN), a medication shown to significantly lower the risk of HIV transmission by 96%. This breakthrough comes after promising trial results in September, which demonstrated its effectiveness in preventing the virus among patients. Advocates like Mitchell Warren emphasize that while this approval is crucial for HIV prevention, it represents only a single step in the ongoing battle against HIV, highlighting the importance of further efforts to integrate LEN into existing health programs to combat the annual 1.3 million new infections worldwide.
The approval of LEN is a much-needed boost for HIV prevention, given the strength of the science and the simultaneous disruption in HIV programs globally.
But US FDA approval is just one in a series of steps needed to ensure that injectable LEN can help reduce the 1.3 million new HIV infections that occur each year.
Collection
[
|
...
]